A pancreas tumor derived organoid study: from drug screen to precision medicine

9Citations
Citations of this article
39Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) one of the deadliest malignant tumor. Despite considerable progress in pancreatic cancer treatment in the past 10 years, PDAC mortality has shown no appreciable change, and systemic therapies for PDAC generally lack efficacy. Thus, developing biomarkers for treatment guidance is urgently required. This review focuses on pancreatic tumor organoids (PTOs), which can mimic the characteristics of the original tumor in vitro. As a powerful tool with several applications, PTOs represent a new strategy for targeted therapy in pancreatic cancer and contribute to the advancement of the field of personalized medicine.

Cite

CITATION STYLE

APA

Yao, J., Yang, M., Atteh, L., Liu, P., Mao, Y., Meng, W., & Li, X. (2021, December 1). A pancreas tumor derived organoid study: from drug screen to precision medicine. Cancer Cell International. BioMed Central Ltd. https://doi.org/10.1186/s12935-021-02044-1

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free